Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amedisys (AMED) delivered earnings and revenue surprises of 1.98% and 1.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 millio
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
UnitedHealth had announced the acquisition in June, after competing with Option Care Health. The acquisition was meant to help expand UnitedHealth's presence in home healthcare, a business it bolstered through a $5.4 billion deal to buy Amedisys' rival, LHC Group, last year.
Amedisys said on Tuesday Oregon's health authority has started a review of UnitedHealth Group's $3.3 billion acquisition of the home health and hospice caregiver. UnitedHealth had announced the acquisition in June, after competing with Option Care Health. The acquisition was meant to help expand UnitedHealth's presence in home healthcare, a business it bolstered through a $5.4 billion deal to buy Amedisys' rival, LHC Group, last year.